ArticleFrontiers in immunology2023
Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors.
Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Immune Checkpoint Inhibitor-Based Adjuvant Treatment Versus Surveillance in Curatively Treated Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis.Journal of gastroenterology and hepatology · 2026Pooled it
- Pooled it
- Can adjuvant immune checkpoint inhibitors improve the long-term outcomes of hepatocellular carcinoma with high-risk recurrent factors after liver resection? A meta-analysis and systematic review.Frontiers in oncology · 2024Pooled it
- Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.Nature medicine · 2024Trial
- Article
- Development and External Validation of a Multimodal Machine Learning Model Integrating Preoperative Contrast-Enhanced CT Radiomics and Clinicopathological Features for Predicting Early Extrahepatic Recurrence After Hepatectomy for Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Comparative efficacy of postoperative adjuvant transcatheter arterial chemoembolization versus lenvatinib plus tislelizumab in patients with BCLC stage 0 -B hepatocellular carcinoma after radical resection.Frontiers in immunology · 2026Article
- Development and Validation of a Machine Learning-Based Individualized Model to Predict TKI Benefit in Postoperative Recurrent HCC.Journal of hepatocellular carcinoma · 2026Article
- Anti-PD-1 therapy for preventing recurrence and improving survival in hepatocellular carcinoma patients after hepatectomy.BMC surgery · 2025Observational
- Adjuvant HAIC combined with anlotinib and TQB2450 for resected high-risk hepatocellular carcinoma.Innovation (Cambridge (Mass.)) · 2025Article
- Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma.World journal of gastrointestinal oncology · 2025Article
- Article
- Tumor Compression of the Hepatic or Portal Vein Predicts the Presence of Microvascular Invasion and Satellite Nodules in Hepatocellular Carcinoma: A Retrospective Study.Journal of hepatocellular carcinoma · 2025Article
- Impact of Middle Hepatic Vein Resection During Hemihepatectomy on Surgical Outcomes and Long-Term Prognosis in Hepatocellular Carcinoma: A Retrospective Study.Journal of hepatocellular carcinoma · 2025Article
- Adjuvant Transarterial Chemoembolization Plus Immunotherapy for Huge Hepatocellular Carcinoma: A Propensity Score Matching Cohort Study.Journal of hepatocellular carcinoma · 2024Article
- Case report: Combination therapy for hepatocellular carcinoma with inferior vena cava or right atrial tumor thrombus in the era of combined targeted and immunotherapeutic agents.Frontiers in oncology · 2024Article
- Importance of optimizing duration of adjuvant immune checkpoint inhibitor therapy to treat postoperative hepatocellular carcinoma after conversion therapy: a case report.Journal of surgical case reports · 2023Article
- Postoperative adjuvant immunotherapy for high-risk hepatocellular carcinoma patients.Frontiers in oncology · 2023Article
- Adjuvant Lenvatinib Plus PD-1 Antibody for Hepatocellular Carcinoma with High Recurrence Risks After Hepatectomy: A Retrospective Landmark Analysis.Journal of hepatocellular carcinoma · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The clinical value of postoperative adjuvant therapy (PAT) for hepatocellular carcinoma (HCC) remains unclear. This study aimed to explore the effect of PAT with tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies on the surgical outcomes of HCC patients with high-risk recurrent factors (HRRFs). Methods: HCC patients who underwent radical hepatectomy at Tongji Hospital between January 2019 and December 2021 were retrospectively enrolled, and those with HRRFs were divided into PAT group and non-PAT group. Recurrence-free survival (RFS) and overall survival (OS) were compared between the two groups after propensity score matching (PSM). Prognostic factors associated with RFS and OS were determined by Cox regression analysis, and subgroup analysis was also conducted. Results: A total of 250 HCC patients were enrolled, and 47 pairs of patients with HRRFs in the PAT and non-PAT groups were matched through PSM. After PSM, the 1- and 2-year RFS rates in the two groups were 82.1% vs. 40.0% ( Conclusions: PAT with TKIs and anti-PD-1 antibodies could improve surgical outcomes for HCC patients with HRRFs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.